Share on StockTwits

Sucampo Pharmaceuticals (NASDAQ:SCMP) major shareholder Ryuji Ueno sold 140,873 shares of the stock on the open market in a transaction dated Monday, August 4th. The shares were sold at an average price of $6.02, for a total transaction of $848,055.46. Following the sale, the insider now directly owns 353,530 shares in the company, valued at approximately $2,128,251. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 3.30% on Tuesday, hitting $6.26. The stock had a trading volume of 256,519 shares. Sucampo Pharmaceuticals has a 1-year low of $5.40 and a 1-year high of $11.00. The stock’s 50-day moving average is $6.71 and its 200-day moving average is $7.42. The company has a market cap of $272.7 million and a P/E ratio of 24.94.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.03 by $0.01. The company had revenue of $24.10 million for the quarter, compared to the consensus estimate of $24.06 million. The company’s quarterly revenue was down 10.7% on a year-over-year basis. On average, analysts predict that Sucampo Pharmaceuticals will post $0.18 earnings per share for the current fiscal year.

SCMP has been the subject of a number of recent research reports. Analysts at Roth Capital initiated coverage on shares of Sucampo Pharmaceuticals in a research note on Friday. They set a “buy” rating and a $9.00 price target on the stock. Analysts at MLV & Co
cut their price target on shares of Sucampo Pharmaceuticals from $14.00 to $11.00 in a research note on Friday, May 9th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.25.

Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.

Receive News & Ratings for Sucampo Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.